Dana-Farber Cancer Institute's Kimberly Stegmaier led a study published yesterday in PNAS that uses a "signature-based screening approach" to identify hits in neuroblastoma treatment. Her team used gene expression analysis to screen a small molecule library, and the top hit was all-trans-retinoic acid. They found that by combining this with an HDAC inhibitor increased neuroblastoma differentiation, which is typically abnormal in this pediatric cancer.
Premium Trial: